Roivant Expects FDA to Approve First Major Drug

Roivant Chief Executive Officer Matt Gline said in an interview with Bloomberg that the company expects FDA approval for a drug to treat a skin disease, with market launch anticipated by September. The company did not specify which skin disease the drug targets. Gline's remarks were made on the Bloomberg program "Open Interest."

Next story